BackLisata Therapeutics Overview

Lisata Therapeutics Total Liabilities

Track Lisata Therapeutics's total liabilities ($3M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$3.04M
30.74% YoYΔ $-1.35M vs prior year quarter

Peer trimmed avg / median

Loading

Lisata Therapeutics Total Liabilities History

Loading

Lisata Therapeutics vs. peers: Total Liabilities Comparison

Loading

Lisata Therapeutics Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Lisata Therapeutics (LSTA) FAQ

Lisata Therapeutics's total liabilities stands at $3M as of June 2026. That compares with $4.4M in the prior-year period — down 30.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Lisata Therapeutics reported $3M in total liabilities versus $4.4M a year earlier — a 30.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $4.4M in the prior-year period — down 30.7% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Lisata Therapeutics's total liabilities evolved across reporting periods, while the comparison chart places LSTA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. Lisata Therapeutics's reading of $3M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.